Patients
Health Information
Product Information Request
Our Products
CephalonCares Foundation Patient Assistance Programs
Reimbursement Assistance
Clinical Trials Information
Healthcare Professionals
Therapeutic Focus
Product Information Request
Our Products
CephalonCares Foundation Patient Assistance Programs
Reimbursement Assistance
Clinical Trials Information
Partners
Business Collaboration
Research Partnerships
Investors
Overview
News Releases
SEC Filings
Stock Information
Dividend/Split History
Corporate Governance
Financial Reports
Analyst Coverage
Ownership Profile
Investor Events
Webcasts and Presentations
Investor FAQ
Literature Request
Email Alerts
Media
News Releases
Media Resources
Featured Profiles
On The Record
Our Company
Message from the Chairman/CEO
Our Story
Our Team
Awards & Recognition
Our Science
Our Scientists
R&D Process
Clinical Trials
Pipeline
Our Responsibility
Business Conduct
Relationships with Healthcare Professionals
CephalonCares Foundation
Commitment to Community
Careers
Employee Benefits
Job Listings
Contact Us
Cephalon Websites
Terms of Use
Privacy
Home
Contact Us
Cephalon Websites
CephalonCares Foundation
Sitemap
Our Company
Our Science
Our Responsibility
Careers
Patients
Healthcare Professionals
Partners
Investors
Media
Search Site
Search
Media
News Releases
By Year
2010
2009
2008
2007
2006
2005
2004
Media Resources
Corporate
Central Nervous System Disorders
Cancer
Pain
Featured Profiles
Healthcare Professionals
Programs
Products
On The Record
Cephalon Response to JAMA Article “The Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain”
Archive
Q&A on Settlements Regarding Investigations into Cephalon Business Practices
Our Commitment to Appropriate Interactions with Healthcare Professionals
Our Position on Tamper-Deterrent Formulation of Extended-Release Opioids
Set the Record Straight About ACTIQ®
Set the Record Straight About PROVIGIL®
Home
>
Media
> News Releases
News Releases:
Heading 5
Sidebar Text area